Genscript Biotech Corporation G51.F Stock
Genscript Biotech Corporation Price Chart
Genscript Biotech Corporation G51.F Financial and Trading Overview
Genscript Biotech Corporation stock price | 1.52 EUR |
Previous Close | 2.18 EUR |
Open | 2.29 EUR |
Bid | 2.26 EUR x 800000 |
Ask | 2.35 EUR x 800000 |
Day's Range | 2.29 - 2.29 EUR |
52 Week Range | 1.87 - 3.99 EUR |
Volume | 1K EUR |
Avg. Volume | 33 EUR |
Market Cap | 5.18B EUR |
Beta (5Y Monthly) | 1.401915 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.04 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | June 6, 2017 |
1y Target Est | N/A |
G51.F Valuation Measures
Enterprise Value | 4.15B EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 8.274232 |
Price/Book (mrq) | 4.770355 |
Enterprise Value/Revenue | 6.628 |
Enterprise Value/EBITDA | -10.659 |
Trading Information
Genscript Biotech Corporation Stock Price History
Beta (5Y Monthly) | 1.401915 |
52-Week Change | -29.61% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.99 EUR |
52 Week Low | 1.87 EUR |
50-Day Moving Average | 2.23 EUR |
200-Day Moving Average | 2.54 EUR |
G51.F Share Statistics
Avg. Volume (3 month) | 33 EUR |
Avg. Daily Volume (10-Days) | 40 EUR |
Shares Outstanding | 2.12B |
Float | 1.14B |
Short Ratio | N/A |
% Held by Insiders | 38.31% |
% Held by Institutions | 24.71% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -36.25% |
Operating Margin (ttm) | -70.019% |
Gross Margin | 48.59% |
EBITDA Margin | -62.17% |
Management Effectiveness
Return on Assets (ttm) | -11.45% |
Return on Equity (ttm) | -31.12% |
Income Statement
Revenue (ttm) | 625.7M EUR |
Revenue Per Share (ttm) | 0.3 EUR |
Quarterly Revenue Growth (yoy) | 23.20% |
Gross Profit (ttm) | N/A |
EBITDA | -389035008 EUR |
Net Income Avi to Common (ttm) | -226851008 EUR |
Diluted EPS (ttm) | -0.1 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.46B EUR |
Total Cash Per Share (mrq) | 0.69 EUR |
Total Debt (mrq) | 656.02M EUR |
Total Debt/Equity (mrq) | 48.14 EUR |
Current Ratio (mrq) | 3.233 |
Book Value Per Share (mrq) | 0.479 |
Cash Flow Statement
Operating Cash Flow (ttm) | -120292000 EUR |
Levered Free Cash Flow (ttm) | -343065376 EUR |
Profile of Genscript Biotech Corporation
Country | Germany |
State | N/A |
City | Nanjing |
Address | Jiangning Science Park |
ZIP | 211100 |
Phone | 86 25 5889 7288 |
Website | https://www.genscript.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 6213 |
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. The company was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
Q&A For Genscript Biotech Corporation Stock
What is a current G51.F stock price?
Genscript Biotech Corporation G51.F stock price today per share is 1.52 EUR.
How to purchase Genscript Biotech Corporation stock?
You can buy G51.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genscript Biotech Corporation?
The stock symbol or ticker of Genscript Biotech Corporation is G51.F.
Which industry does the Genscript Biotech Corporation company belong to?
The Genscript Biotech Corporation industry is Biotechnology.
How many shares does Genscript Biotech Corporation have in circulation?
The max supply of Genscript Biotech Corporation shares is 2.12B.
What is Genscript Biotech Corporation Price to Earnings Ratio (PE Ratio)?
Genscript Biotech Corporation PE Ratio is now.
What was Genscript Biotech Corporation earnings per share over the trailing 12 months (TTM)?
Genscript Biotech Corporation EPS is -0.04 EUR over the trailing 12 months.
Which sector does the Genscript Biotech Corporation company belong to?
The Genscript Biotech Corporation sector is Healthcare.